“科兴争夺战”的最新三大焦点

Core Viewpoint - The control of Sinovac remains unresolved as disputes arise among shareholders regarding the legitimacy of a special shareholders' meeting and board changes [1][2][3] Group 1: Shareholder Disputes - The special shareholders' meeting held on July 9 aimed to vote on two proposals: the removal of the current board members and the election of ten new directors nominated by Sequoia Capital [1][5] - The shareholders are divided into two factions: the original board led by founder Yin Weidong and the current board led by Li Jiaqiang [1][2] - The legality of the meeting called by Sequoia Capital and the newly formed board is under dispute, with claims of illegitimacy from both sides [3][6] Group 2: Board Composition and Voting - The proposed new board candidates include Simon Anderson, Fu Shan, Jiao Shuge, Li Jiaqiang, and others, with significant representation from Sequoia Capital and VIVO Capital [4][5] - Sequoia Capital claims that the shareholders approved their proposals during the special meeting, while Li Jiaqiang's side contests the validity of this claim [5][6] Group 3: Legal Proceedings and Court Rulings - Li Jiaqiang's faction argues that the special meeting was legally adjourned and that any subsequent meeting held without his presence lacks legal authority [3][6] - The ongoing legal disputes include the validity of PIPE shares held by VIVO Capital and Shangcheng Capital, with conflicting court rulings regarding their participation in the voting process [7][8] - The Antigua court has previously ruled against the legitimacy of the board elected in 2018, which has implications for the current governance structure [9][10]